From the Journals

Breast cancer family history linked to better BC survival


 

TOPLINE:

A family history of breast cancer does not necessarily mean that women who have the disease are more likely to die from it.

METHODOLOGY:

  • Investigators reviewed 28,649 Swedish women diagnosed with breast cancer from 1991 to 2019.
  • Overall, 5,081 patients (17.7%) had at least one female first-degree relative previously diagnosed with breast cancer.

TAKEAWAYS:

  • After adjusting for demographics, tumor characteristics, and treatments, a family history of breast cancer was associated with a lower risk of breast cancer–specific death in the full cohort (hazard ratio, 0.78) and in ER-negative women (HR, 0.57) within 5 years of diagnosis, after which point the association was no longer significant.
  • The lower risk of death among women with a family history could mean that these women are more motivated and likely to get screened, potentially catching tumors earlier, and may be more likely to adhere to treatment recommendations.
  • However, having a family history of early-onset breast cancer (before the age of 40) was associated with a higher risk of breast cancer–specific death (HR, 1.41).

IN PRACTICE:

Although the findings are reassuring for many women with breast cancer, “genetic testing of newly diagnosed patients with early-onset family history may provide useful information to aid treatment and future research,” the researchers concluded.

STUDY DETAILS:

The study was led by Yuqi Zhang, PhD, of the Karolinska Institutet, Stockholm, and published in JAMA Network Open.

LIMITATIONS:

  • The main analysis did not include tumor characteristics only available within the last 20 years, including ERBB2 status.
  • Relatively wide confidence intervals make the association between a family history of early-onset breast cancer and higher risk of breast cancer death somewhat uncertain.

DISCLOSURES:

  • The work was funded by the Swedish Cancer Society and others.
  • The investigators report no relevant financial relationships.

A version of this article originally appeared on Medscape.com.

Recommended Reading

In TNBC, repeated biopsies may reveal emergent HER2-low expression
Federal Practitioner
New study backs up capecitabine dosing practice in metastatic BC
Federal Practitioner
Less therapy may suit older patients with breast cancer
Federal Practitioner
‘New standard of care’ for capecitabine hand-foot syndrome
Federal Practitioner
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
Federal Practitioner
Low-carb, plant-rich diets tied to breast cancer survival?
Federal Practitioner
ASCO 2023: Promising results in breast cancer from NATALEE and PHERGain
Federal Practitioner
‘Professional grief’ is a daily reality for oncologists
Federal Practitioner
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
Federal Practitioner
T-DXd active in many solid tumors; ‘shift in thinking’
Federal Practitioner